EBS - Emergent Bio reports positive two-year data from mid-stage CHIKV VLP study

Emergent BioSolutions (EBS) announces two-year data from its Phase 2 clinical study evaluating the safety and immunogenicity of investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.Emergent’s CHIKV VLP vaccine continued to demonstrate a favorable safety profile and had generated a dose-related increase in neutralizing antibody response against the chikungunya virus as previously reported.Two years post-vaccination, serum neutralizing antibodies ((SNA)) responses were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose of the CHIKV VLP vaccine, supporting the persistence of the immune response.The vaccine candidate was well-tolerated and no significant safety concerns were identified. The majority of solicited adverse events were mild or moderate in severity. The data were presented at the International Society of Travel Medicine ((ISTM)) annual meeting held May 19 to 22, 2021.The company intends to publish the results of this study in the near-term.

For further details see:

Emergent Bio reports positive two-year data from mid-stage CHIKV VLP study